

Anthrax Vaccine Work Group

**David S. Stephens, MD, FIDSA
ACIP Anthrax Vaccine Work Group**

**Advisory Committee for
Immunization Practices
October 24, 2018**

ACIP Anthrax Work Group Members

ACIP Members: David Stephens, Chair; Robert L. Atmar; Sharon Frey

Ex Officio Members: Judy Hewitt (NIH); Amanda Zarrabian (BARDA); Alexandra Worobec (FDA); Eric Deussing (DOD); Kim Taylor (NIH); Chia-Wei Tsai (BARDA); Julianne Clifford (FDA)

Liaison Representatives: Richard Beigi (ACOG); Kathleen Neuzil (IDSA) ; James Campbell (AAP); Matthew Zahn (NACCHO)

Invited Consultants: Wendy Keitel; Arthur Friedlander; Phillip Pittman; Andy Pavia, Stacy Hall

CDC: William Bower, Lead

Anthrax Vaccine Work Group Activities

❑ Reconvened in March 2017

❑ Purpose

- The US government stockpiles anthrax vaccine and antitoxin for **postexposure prophylaxis (PEP)** should there be a **wide-area release of *Bacillus anthracis* spores**
- The work group considered the body of evidence since last review in 2010 for policy changes to optimize the use of anthrax vaccine for postexposure prophylaxis (PEP) following a wide-area release of *Bacillus anthracis* spores
- The work group is also reviewing the body of evidence for use of anthrax antitoxin for PEP when no effective antimicrobials are available

Today's session

- ❑ **Informational session on new anthrax vaccine (AV7909) for postexposure prophylaxis**
- ❑ **Informational session on anthrax antitoxin for postexposure prophylaxis**